Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.41 |
| ▸ | ICMT | O60725 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602094 | 0.92 | GLA (0.42) | PTPN1F2RL3PLA2G2AGLASERPINE1 | |
| SCHEMBL3583780 | 0.88 | F2RL3 (0.47) | PTPN1F2RL3PLA2G2AGLASERPINE1 | |
| SCHEMBL3592319 | 0.88 | GLA (0.52) | PTPN1F2RL3GLAL3MBTL1MAPK1 | |
| SCHEMBL13254021 | 0.87 | PLA2G2A (0.54) | PTPN1PLA2G2ASERPINE1 | |
| SCHEMBL3585213 | 0.85 | PLA2G2A (0.44) | PTPN1F2RL3PLA2G2A | |
| SCHEMBL3598928 | 0.85 | F2RL3 (0.48) | PTPN1F2RL3SERPINE1L3MBTL1 | |
| SCHEMBL3600671 | 0.83 | PTPN1 (0.47) | PTPN1F2RL3GLASERPINE1MAPK1 | |
| SCHEMBL3600338 | 0.83 | GLA (0.43) | PTPN1F2RL3GLASERPINE1MAPK1 | |
| SCHEMBL3598494 | 0.82 | F2RL3 (0.45) | PTPN1F2RL3GLASERPINE1MAPK1 | |
| SCHEMBL13254027 | 0.82 | PTPN1 (0.41) | PTPN1F2RL3GLASERPINE1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | PTPN1 752/4885F2RL3 555/4885PLA2G2A 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.